신경병증성 통증 시장 규모 조사 : 약물 유형별, 적응증별, 유통 채널별, 지역별 예측(2022-2032년)

The Global Neuropathic Pain Market is valued approximately at USD 8.14 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.73% over the forecast period 2024-2032. Neuropathic pain, caused by damage or disease affecting the somatosensory nervous system, is often linked to abnormal sensations such as dysesthesia, or continuous and paroxysmal components. Common symptoms include burning or coldness, pins and needles, numbness, and itching. Medications like opioids, capsaicin, anticonvulsants, and antidepressants are commonly used for neuropathic pain management. Furthermore, the aging population, which is more prone to conditions such as diabetes and shingles leading to neuropathic pain, drives the market. The growing global burden of chronic diseases associated with nerve damage, such as HIV, postherpetic neuralgia, trigeminal neuralgia, and fibromyalgia, also contributes to market expansion. For instance, according to UNAIDS, 39 million people were living with HIV in 2022, with a significant portion experiencing neuropathic pain due to peripheral neuropathy.

The market is driven by the increasing demand for drugs for neuropathic pain, growing awareness initiatives by various government associations, and a rise in clinical trials for neuropathic pain treatments. For instance, in May 2023, Algiax Pharmaceuticals announced the continuation of its Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain, following a positive mid-enrollment interim analysis. Moreover, the rise in the prevalence of conditions causing neuropathic pain, such as spinal stenosis and diabetic neuropathy, is a key factor driving market growth. Additionally, chemotherapy-induced peripheral neuropathy, a common side effect of cancer treatments, further propels the demand for neuropathic pain medications. According to the American Cancer Society, numerous new cancer cases were diagnosed in the U.S. in 2021, emphasizing the need for effective pain management solutions. However, challenges such as high cost of drug development and stringent regulatory approvals restrain demand for the Global Neuropathic Pain Market during the forecast period 2024-2032.

The key regions considered for the Global Neuropathic Pain Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. In 2023, North America was the dominating regional market in terms of revenue. The region boasts advanced healthcare infrastructure and high healthcare expenditure, which facilitates extensive research and development in pain management therapies. The prevalence of chronic diseases, such as diabetes and cancer, which often lead to neuropathic pain, is relatively high in North America, driving demand for effective treatments. Furthermore, the presence of major pharmaceutical companies and research institutions accelerates the development and commercialization of innovative neuropathic pain medications and therapies. Regulatory bodies like the FDA provide a structured pathway for drug approvals, ensuring a steady pipeline of new treatments. Additionally, growing awareness about neuropathic pain among healthcare professionals and patients, along with strong support from healthcare insurance systems, further boosts the market. Furthermore, the Asia-Pacific region is expected to grow at the fastest rate over the forecast period 2024-2032.

Major market players included in this report are:

• Abbott Laboratories
• Collegium Pharmaceutical, Inc.
• Eli Lilly and Company
• Glenmark Pharmaceuticals Limited
• Grunenthal
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd

The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Antidepressants
• Tricyclic Antidepressants
• Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
• Anticonvulsant
• Opioids
• Capsaicin
• Others

By Indication:

• Diabetic Neuropathy
• Spinal Stenosis
• Chemotherapy-Induced Peripheral Neuropathy
• Others

By Distribution Channel:

• Hospital Pharmacies
• Drugs Stores and Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• China
• Japan
• Australia
• India
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Neuropathic Pain Market Executive Summary

• 1.1. Global Neuropathic Pain Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug Class
  • 1.3.2. By Indication
  • 1.3.3. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Neuropathic Pain Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Neuropathic Pain Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rise in Cases of Spinal Stenosis and Diabetic Neuropathy
  • 3.1.2. Increase in Prevalence of Chronic Diseases
  • 3.1.3. Growing Geriatric Population
• 3.2. Market Challenges
  • 3.2.1. High Cost of Drug Development
  • 3.2.2. Stringent Regulatory Approvals
• 3.3. Market Opportunities
  • 3.3.1. Advances in Drug Development Technologies
  • 3.3.2. Expansion in Emerging Markets
  • 3.3.3. Rising Investments in Research and Development

Chapter 4. Global Neuropathic Pain Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Neuropathic Pain Market Size & Forecasts by Drug Class 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Neuropathic Pain Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Antidepressants
    • 5.2.1.1. Tricyclic Antidepressants
    • 5.2.1.2. Serotonin-Noradrenaline Reuptake Inhibitors (SNRI)
  • 5.2.2. Anticonvulsant
  • 5.2.3. Opioids
  • 5.2.4. Capsaicin
  • 5.2.5. Others

Chapter 6. Global Neuropathic Pain Market Size & Forecasts by Indication 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Neuropathic Pain Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Diabetic Neuropathy
  • 6.2.2. Spinal Stenosis
  • 6.2.3. Chemotherapy-Induced Peripheral Neuropathy
  • 6.2.4. Others

Chapter 7. Global Neuropathic Pain Market Size & Forecasts by Distribution Channel 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Neuropathic Pain Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Drugs Stores and Retail Pharmacies
  • 7.2.3. Online Pharmacies

Chapter 8. Global Neuropathic Pain Market Size & Forecasts by Region 2022-2032

• 8.1. North America Neuropathic Pain Market
  • 8.1.1. U.S. Neuropathic Pain Market
    • 8.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
    • 8.1.1.2. Indication breakdown size & forecasts, 2022-2032
    • 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
  • 8.1.2. Canada Neuropathic Pain Market
• 8.2. Europe Neuropathic Pain Market
  • 8.2.1. Germany Neuropathic Pain Market
  • 8.2.2. UK Neuropathic Pain Market
  • 8.2.3. France Neuropathic Pain Market
  • 8.2.4. Italy Neuropathic Pain Market
  • 8.2.5. Spain Neuropathic Pain Market
  • 8.2.6. Rest of Europe Neuropathic Pain Market
• 8.3. Asia-Pacific Neuropathic Pain Market
  • 8.3.1. China Neuropathic Pain Market
  • 8.3.2. Japan Neuropathic Pain Market
  • 8.3.3. Australia Neuropathic Pain Market
  • 8.3.4. India Neuropathic Pain Market
  • 8.3.5. South Korea Neuropathic Pain Market
  • 8.3.6. Rest of Asia Pacific Neuropathic Pain Market
• 8.4. Latin America Neuropathic Pain Market
  • 8.4.1. Brazil Neuropathic Pain Market
  • 8.4.2. Mexico Neuropathic Pain Market
  • 8.4.2. Rest of Latin America Neuropathic Pain Market
• 8.5. Middle East & Africa Neuropathic Pain Market
  • 8.5.1. Saudi Arabia Neuropathic Pain Market
  • 8.5.2. South Africa Neuropathic Pain Market
  • 8.5.3. Rest of Middle East & Africa Neuropathic Pain Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Abbott Laboratories
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Collegium Pharmaceutical, Inc.
  • 9.3.3. Eli Lilly and Company
  • 9.3.4. Glenmark Pharmaceuticals Limited
  • 9.3.5. Grunenthal
  • 9.3.6. Mallinckrodt Pharmaceuticals
  • 9.3.7. Novartis AG
  • 9.3.8. Pfizer Inc.
  • 9.3.9. Sun Pharmaceutical Industries Ltd.
  • 9.3.10. Teva Pharmaceutical Industries Ltd.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes